![](https://news.europawire.eu/wp-content/uploads/2016/12/Research-looks-into-the-impact-and-cost-effectiveness-of-the-Dengvaxia-vaccine-under-a-host-of-varying-conditions-144x144.jpg)
Exeter, UK, 01-Dec-2016 — /EuropaWire/ — The first licensed vaccine for the potentially life-threatening dengue virus should only be used in moderate-to high impacted regions, new research has predicted. A team of international researchers, including Dr Mario Recker from the University … Read the full press release